ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT06580717

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06580717
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06580717. Randomized; single masking; primary purpose treatment. Start 2024-10-15 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
Condition
Nonobstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
enavogliflozin 0.3mg
Intervention (Drug)
enavogliflozin Placebo
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct06580717
Content hash
558d82032961b4dd4d4f8ed3485fb7d20d31e4ff894b90c8f39f02aadd134416